Revenue grew 8.93% year-over-year to RMB 2.16 billion, but the company posted a net loss of RMB 241 million due to increased R&D spending and lower caffeine product margins. Biopharma revenue surged, and the company expanded its pipeline and global partnerships.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.